Johnson & Johnson (JNJB34.SA)

São Paulo - São Paulo Delayed Price. Currency in BRL

Add to watchlist

57.22

+0.49

(+0.86%)

At close: 05:06PM BRT

Advertisement

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Neutralpattern detected

All

Benzinga
ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug
Immix Biopharma Inc (NASDAQ: IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS). STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for trabectedin in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. Trabectedin is sold as Yondelis by Janssen, a Johnson & Johnson (NYSE: JNJ) com
- ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
  GlobeNewswire
- Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair
  Business Wire
Zacks
Best ETFs for High Inflation and Rising Rates
We discuss areas that could outperform in the current market environment.
MoneyWise
How can I stop the pain and make money in this nightmarish market? BofA says this is the ‘best hope’ for bulls in 2022
Companies could be returning trillions to shareholders. Here’s how to accept it.

Advertisement